Encoding laboratory testing data: case studies of the national implementation of HHS requirements and related standards in five laboratories.

Logical Observation Identifiers Names and Codes clinical laboratory information systems health information interoperability public reporting of healthcare data

Journal

Journal of the American Medical Informatics Association : JAMIA
ISSN: 1527-974X
Titre abrégé: J Am Med Inform Assoc
Pays: England
ID NLM: 9430800

Informations de publication

Date de publication:
12 07 2022
Historique:
received: 17 02 2022
accepted: 27 04 2022
pubmed: 1 6 2022
medline: 15 7 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Assess the effectiveness of providing Logical Observation Identifiers Names and Codes (LOINC®)-to-In Vitro Diagnostic (LIVD) coding specification, required by the United States Department of Health and Human Services for SARS-CoV-2 reporting, in medical center laboratories and utilize findings to inform future United States Food and Drug Administration policy on the use of real-world evidence in regulatory decisions. We compared gaps and similarities between diagnostic test manufacturers' recommended LOINC® codes and the LOINC® codes used in medical center laboratories for the same tests. Five medical centers and three test manufacturers extracted data from laboratory information systems (LIS) for prioritized tests of interest. The data submission ranged from 74 to 532 LOINC® codes per site. Three test manufacturers submitted 15 LIVD catalogs representing 26 distinct devices, 6956 tests, and 686 LOINC® codes. We identified mismatches in how medical centers use LOINC® to encode laboratory tests compared to how test manufacturers encode the same laboratory tests. Of 331 tests available in the LIVD files, 136 (41%) were represented by a mismatched LOINC® code by the medical centers (chi-square 45.0, 4 df, P < .0001). The five medical centers and three test manufacturers vary in how they organize, categorize, and store LIS catalog information. This variation impacts data quality and interoperability. The results of the study indicate that providing the LIVD mappings was not sufficient to support laboratory data interoperability. National implementation of LIVD and further efforts to promote laboratory interoperability will require a more comprehensive effort and continuing evaluation and quality control.

Identifiants

pubmed: 35639494
pii: 6592172
doi: 10.1093/jamia/ocac072
pmc: PMC9277627
doi:

Banques de données

Dryad
['10.5061/dryad.0cfxpnw55']

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1372-1380

Subventions

Organisme : U.S. Food and Drug Administration Office of In Vitro Diagnostics and Radiological Health
Organisme : Center for Devices and Radiological Health
ID : # 75F40119C10164
Organisme : Implementation of SHIELD Harmonized Laboratory Data Standards in Healthcare Institutions
Organisme : U.S. Food and Drug Administration Office of In Vitro Diagnostics and Radiological Health within the Center for Devices and Radiological Health
ID : 75F40119C10164

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the American Medical Informatics Association.

Références

J Oncol Pract. 2019 Jan;15(1):3-6
pubmed: 30566370
Arch Pathol Lab Med. 2020 May;144(5):586-596
pubmed: 31603714
J Biomed Inform. 2012 Aug;45(4):651-7
pubmed: 22210167
J Biomed Inform. 2012 Aug;45(4):658-66
pubmed: 22306382
Int J Med Inform. 1998 Jul;51(1):29-37
pubmed: 9749897
Arch Pathol Lab Med. 2020 Feb;144(2):229-239
pubmed: 31219342
Online J Public Health Inform. 2020 Dec 08;12(2):e14
pubmed: 33381280
Methods Inf Med. 2011;50(2):105-14
pubmed: 20725694
J Am Med Inform Assoc. 2011 Jan-Feb;18(1):99-103
pubmed: 21106995
Lancet Digit Health. 2019 Dec;1(8):e387-e388
pubmed: 33323218
Lancet Digit Health. 2020 Nov;2(11):e569
pubmed: 33328084
Lab Med. 2015 Spring;46(2):168-74
pubmed: 25918199

Auteurs

Raja A Cholan (RA)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

Gregory Pappas (G)

Office of the National Coordinator for Health Information Technology, Washington, District of Columbia, USA.
U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Greg Rehwoldt (G)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

Andrew K Sills (AK)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

Elizabeth D Korte (ED)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

I Khalil Appleton (IK)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

Natalie M Scott (NM)

Deloitte Consulting LLP, Washington, District of Columbia, USA.

Wendy S Rubinstein (WS)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Sara A Brenner (SA)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
U.S. Department of Health and Human Services, Silver Spring, Maryland, USA.

Riki Merrick (R)

Association for Public Health Laboratories, Silver Spring, Maryland, USA.

Wilbur C Hadden (WC)

University of Maryland, College Park, Maryland, USA.

Keith E Campbell (KE)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
U.S. Department of Veterans Affairs, Bend, Oregon, USA.

Michael S Waters (MS)

U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH